» Articles » PMID: 23804564

Reverse Transcriptase Backbone Can Alter the Polymerization and RNase Activities of Non-nucleoside Reverse Transcriptase Mutants K101E+G190S

Overview
Journal J Gen Virol
Specialty Microbiology
Date 2013 Jun 28
PMID 23804564
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Previous work by our group showed that human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) containing non-nucleoside RT inhibitor (NNRTI) drug resistance mutations has defects in RNase H activity as well as reduced amounts of RT protein in virions. These deficits correlate with replication fitness in the absence of NNRTIs. Viruses with the mutant combination K101E+G190S replicated better in the presence of NNRTIs than in the absence of drug. Stimulation of virus growth by NNRTIs occurred during the early steps of the virus life cycle and was modulated by the RT backbone sequence in which the resistance mutations arose. We wanted to determine what effects RT backbone sequence would have on RT content and polymerization and RNase H activities in the absence of NNRTIs. We compared a NL4-3 RT with K101E+G190S to a patient-isolate RT sequence D10 with K101E+G190S. We show here that, unlike the NL4-3 backbone, the D10 backbone sequence decreased the RNA-dependent DNA polymerization activity of purified recombinant RT compared to WT. In contrast, RTs with the D10 backbone had increased RNase H activity compared to WT and K101E+G190S in the NL4-3 backbone. D10 virions also had increased amounts of RT compared to K101E+G190S in the NL4-3 backbone. We conclude that the backbone sequence of RT can alter the activities of the NNRTI drug-resistant mutant K101E+G190S, and that identification of the amino acids responsible will aid in understanding the mechanism by which NNRTI drug-resistant mutants alter fitness and NNRTIs stimulate HIV-1 virus replication.

Citing Articles

The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy.

Wang Y, Xing H, Liao L, Wang Z, Su B, Zhao Q AIDS Res Ther. 2015; 11:36.

PMID: 25926857 PMC: 4414387. DOI: 10.1186/1742-6405-11-36.

References
1.
Chesebro B, Wehrly K, Nishio J, Perryman S . Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol. 1992; 66(11):6547-54. PMC: 240149. DOI: 10.1128/JVI.66.11.6547-6554.1992. View

2.
Betancor G, Puertas M, Nevot M, Garriga C, Martinez M, Martinez-Picado J . Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure. Antimicrob Agents Chemother. 2010; 54(11):4799-811. PMC: 2976120. DOI: 10.1128/AAC.00716-10. View

3.
Chung S, Miller J, Johnson B, Hughes S, Le Grice S . Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity. J Biol Chem. 2011; 287(6):4066-75. PMC: 3281700. DOI: 10.1074/jbc.M111.314781. View

4.
Perez-Alvarez L, Carmona R, Munoz M, Delgado E, Thomson M, Contreras G . High incidence of non-B and recombinant HIV-1 strains in newly diagnosed patients in Galicia, Spain: study of genotypic resistance. Antivir Ther. 2003; 8(4):355-60. View

5.
Gupta S, Vingerhoets J, Fransen S, Tambuyzer L, Azijn H, Frantzell A . Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens. Antimicrob Agents Chemother. 2011; 55(6):2872-9. PMC: 3101386. DOI: 10.1128/AAC.01695-10. View